Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Lennox Gastaut Syndrome 1Epilepsy 1Epilepsies, Myoclonic 1

Interventions

Cisplatin 186Carboplatin 181Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 81Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has results × Cannabidiol × Clear all
NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Jazz Pharmaceuticals

Phase 3 Terminated
3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT02544763 2022-09-28

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
224 enrolled 18 charts

Seizures, Tuberous Sclerosis

NCT02544750 2022-07-14

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
199 enrolled 14 charts

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡